If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

Title: A021806, A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:

Poulose MD, Joyson

Sponsors: National Cancer Institute
Details (Identifier #): NCT04340141
Title: A151216 ALCHEMIST, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator:

Lash MD, Bradley

Sponsors: ALLIANCE
Details (Identifier #): NCT02194738
Title: ALLIANCE A222004:
A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA
Department: Oncology
Diagnosis: Not applicable
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT04964934
Title: EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Department: Oncology
Diagnosis: Melanoma
Principal Investigator:

Lash MD, Bradley

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT02339571
Title: ICECAP - Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
Department: Emergency Medicine
Diagnosis: Cardiac - Miscellaneous
Principal Investigator:

Rittenberger MD, Jon

Sponsors: SIREN
Details (Identifier #): NCT04217551
Title: Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT05710328
Title: LIBREXIA-AF A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator:

Kaluski MD, Edo

Sponsors: Janssen Research & Development, LLC
Details (Identifier #): NCT05757869
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator:

McDonald M.D., Thomas

Sponsors: Janssen Scientific Affairs, LLC
Details (Identifier #): none
Showing 11-20 of 40 Results